The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
To achieve capital growth through investing in high growth, development stage biotechnology companies.
Find out MoreLondon South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looks like the share price went up and now record highs! I am still in, botech sector as I still see value but totally understand than US stocks could be due a fall and this 85% North America. There are UK and European biopharmaceutical funds if the fundmangers to not switch.
Well done forgiving info on this board Sheepy. Good luck and best wishes for the future.
I'm out. Don't see it going up as fast as I expected so it's time to say goodbye. Will try somewhere else.
Don't give up on GILD stock yet -- go long for free By Nicolas Chahine, InvestorPlace Contributor | Sep 29, 2017, 9:59 am EDT Gilead Sciences, Inc. (NASDAQ:GILD) stock suffered a nasty 50% correction from its $123 per share high. It finally found footing in June of this year. The slide started mid 2015 and the stock set a lower high and the lower low until it was finally able to stabilize around $64.00 per share. And therein lies my opportunity. GILD Stock: Gilead Sciences, Inc. (GILD) Stock Gots Its Mojo Back Source: Gilead Sciences A stock price bottom that takes this long to set becomes a solid floor. In addition, it is a significant level because it has been in contention since 2013, over four years ago. It was then when the bulls broke out from it and have used it as support ever since. In the past three months, Gilead stock rallied 25% off the aforementioned bottom. But it is important to note that the momentum faded around $85 per share. This is another point of contention that dates back to early 2014. So for now it looks like the bears will hold it has forward resistance.
https://seekingalpha.com/article/4105041-biotech-bonanza-key-piece-falls-place
Vertex Pharmaceuticals Inc. on Tuesday released clinical findings showing its new approach to combating cystic fibrosis substantially improved lung function in patients, lifting hopes for a treatment that could be used by about 68,000 people worldwide — including 24,000 who don’t respond to any existing medicines. The results prompted Boston-based Vertex to say it plans to launch one or two late-stage clinical trials of the biotech’s three-drug combination in the first half of next year. VRTX price popped up today over 20%.
http://www.barrons.com/articles/biotech-2q17-its-mostly-all-gravy-1499953599 "SunTrust Robinson Humphrey's biotechnology team expects Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Celgene (CELG), Clovis Oncology (CLVS), Incyte (INCY), Sarepta Pharmaceutical (SRPT), and Tesaro (TSRO) to beat consensus revenue estimates. Regeneron (REGN) and Seattle Genetics (SGEN), on the other hand, "are likely to report in-line results." Another rosy prediction for the sector- http://www.investopedia.com/news/bull-flag-forming-biotech-etf/
Vertex Pharmaceuticals shares soared on Wednesday after the company announced two positive phase 3 trial results for a cystic fibrosis combination treatment. Vertex said it plans to file for U.S. and European approval for the combination of tezacaftor and ivacaftor in the third quarter of 2017, with decisions likely in the first half of 2018. Cystic fibrosis is a genetic disease that affects more than 30,000 people in the U.S., according to the Cystic Fibrosis Foundation. Symptoms vary by individual but can include lung infections, growth issues, shortness of breath and infertility in men.
INCY stock have popped 8% today thanks to rumors that the company is nearing a deal with Gilead.
Only recently I broke even here. Good thing they will pay dividend. This one is definitely to be kept for long term, I mean ten years plus. Moreover it's mostly denominated in US dollars.
Glad to see there's another shareholder!
Looks as though they are voting on offering a divident on this share/IT which would be nice !
Could be a good topping up point. I still feel that biotech has a lot of life left in it - and these people definitely know what they're doing.
Ouch!
(Reuters) - AbbVie Inc (ABBV.N) is to buy Pharmacyclics Inc (PCYC.O) for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. The deal -- the latest example of a big drugmaker swooping on a biotech firm to refill its medicine pipeline -- confounds expectations that Pharmacyclics would sell out to Johnson & Johnson (JNJ.N). AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Back in 2008 and 2009, the shares dipped below $1. The acquisition lessens Chicago-based AbbVie's dependence on its blockbuster rheumatoid arthritis drug Humira that accounts for most of its revenue but is expected to start to see sales decline from 2017 or 2018. AbbVie failed last October to buy Dublin-based Shire Plc (SHP.L) for $55 billion after the United States took steps to deter such tax-lowering deals. Deutsche Bank analyst Robyn Karnauskas said the deal was positive for AbbVie as Pharmacyclics' blood cancer treatment Imbruvica would diversify the business beyond Humira. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical efficacy across a broad range of hematologic malignancies," AbbVie Chief Executive Richard Gonzalez said in a statement. Pharmacyclics expects U.S. sales of Imbruvica to hit $1 billion this year and by 2020 worldwide sales are forecast to reach $5.8 billion, according to consensus analyst estimates compiled by Thomson Reuters Cortellis. AbbVie, which was spun out of Abbott Laboratories in 2013, said the deal would be "highly accretive" to its revenue and earnings by 2017. Sunnyvale, California-based Pharmacyclics co-markets Imbruvica with Johnson & Johnson. Besides Imbruvica, it has three product candidates in development. In a statement, J&J said: “We’re looking forward to continuing our collaboration with the team at AbbVie to further develop and commercialize this important therapy for patients and their health care teams.” Media reports had said J&J was close to buying Pharmacyclics. Novartis AG (NOVN.VX) was also interested in the company, a report said. The acquisition is the latest in a spate of big pharma deals this year as many companies are strengthening their portfolios as old drugs go generic. Last month, Pfizer Inc (PFE.N) agreed to buy Hospira Inc (HSP.N) for about $15 billion, and Canada's Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) agreed to buy Salix Pharmaceuticals Ltd (SLXP.O) for about $10 billion. The deal, expected to close in the middle of the year, comprises about 58 percent cash and 42 percent AbbVie common stock. Pharmacyclics shareholders can opt for cash, AbbVie stock or a combination, AbbVie said.
I bought these in October 2014 @ 3.70 and I intend to hold long term
one of the best performers does 10x better than ftse100 no1 buys this?
in profit now
big jump today celg all time high 125 gild 104
i got mine as it started to go down lowest price 464 question is WHY DO WE PLAY STAMP DUTY ON MUTUAL FUND SO DUMB i buy us biotechs the same 1s as this fund holds and theres no tax for buying shares part form dumbass uk
Topped up with quite a big chunk. But that was on Jan 20 so still under water on those.
any1 bought anymore
Been waiting to buy Bought half this morning half for later
20%+ discount to the funds NAV. Never before have I seen so much! The UK must believe biotecs in the US are doomed all year.. yet they grow.
Discount % = 18.05 12M Avg Discount % = 13.62 The 5% difference could be erased fairly quickly IMO, 13% seems to be a bit of a resistance level since February.